Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move:
(CSE: $TER.C)
(CSE: $TTT.C), (TSX: $VFF.TO) (NASDAQ: $VFF), (TSX: $ALEF.TO), (TSXV: $EMH.V) (OTC: $HEMP),
(TSXV: $ENW.V)
Delta, Kelowna, BC –October 7, 2019 (Investorideas.com
Newswire) www.Investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/10071TER-TTT-VFF-ALEF-EMH-HEMP-ENW.asp
Good afternoon and welcome to another episode of
Investorideas.com "Potcast" featuring cannabis news, stocks to watch
as well as insights from thought leaders and experts
In
today’s podcast we look at a few early announcements.
But
first, RYAH Medtech, Inc., a big
data and technology company focused on valuable predictive analysis in the
global medical plant intake industry, released a data analytics report on
chronic pain and cannabis. The data, taken from RYAH’s proprietary data pool,
and related insights, examine medical cannabis pain patient demographics and
how different types of chronic pain respond to different strains of medical
cannabis.
"Pain
is a top concern for medical cannabis patients visiting physicians and
dispensaries and we hope that this report will help inform the public on how
some patients are personalizing their cannabis treatments to achieve better
outcomes. As a company rooted in big data and predictive analysis, RYAH is
uniquely positioned to use our artificial intelligence platform to provide
insights on the complete medical plant life cycle from seed to consumption,”
said Gregory Wagner, Chief Executive Officer of RYAH.
The
report found that pain is the 4th most popular reason medical
cannabis patients seek treatment, with slightly more men than women treating
their pain with cannabis. Both groups of patients experienced comorbidities
including anxiety, depression, stress, insomnia and mood swings.
In terms
of strain preference, patients rated Indica and Indica dominant hybrids as
providing the most symptom relief. Examples of some of these Indica dominant
strains include Blueberry Diesel, Mango, and LA Confidential. Patients also
preferred strains with percentages of THC above 15%, considered to be a
relatively high concentration of THC. One of the more unexpected findings was
that CBD content did not seem to play a major role in terms of symptom relief.
TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF) today announced that it has received approval from Health
Canada for significant expansion at its facility in Mississauga, Ontario. This
approval increases licensed space at the Mississauga facility nearly three-fold
from 17,800 sq. ft. to 51,800 sq. ft., and includes additional cultivation
capacity, a commercial kitchen, formulation rooms and increased primary and
secondary packaging capacity to allow for new product formats and extracts for
the Canadian Cannabis 2.0 market.
"Achieving
this approval milestone is a crucial step in our plan to cultivate premium
grade cannabis at scale for distribution to the EU and other international
markets," said Michael Nashat, CEO of TerrAscend. "In addition, our
newly licensed processing operations pave the way for TerrAscend to meet the
significant increased consumer demand expected upon the launch of Cannabis 2.0.
Over the coming months, we plan on introducing the Canadian market to the
proven brands and formulations from our US operations, as well as new
proprietary dosage forms developed in our EU GMP certified Ontario-based
facility."
First
licensed for cultivation in July 2017, TerrAscend's 67,300 sq. ft. GMP
certified indoor cannabis facility located in Mississauga, Ontario, is focused
on serving the Canadian medical and adult-use markets, conducting research
& development for plant sciences and formulations, and serving as a
platform for export of cannabis products to Europe and other international
jurisdictions.
TruTrace Technologies Inc. (CSE: TTT) (OTCQB: TTTSF) and Sigma
Analytical Services, a provider of comprehensive testing and analytical
services for the cannabis industry, today announced that the two companies have entered into a
letter of intent to establish a strategic working relationship.
Pursuant
to the LOI, TruTrace plans to include Sigma Analytical as a genetics
verification and testing partner in its blockchain-secured traceability
ecosystem, and the parties will explore development and integration
opportunities to rapidly expedite and optimize testing processes in the
cannabis and hemp industries.
Sigma
Analytical is also expected to participate in the TruTrace Technologies and
Shoppers Drug Mart medical cannabis verification pilot program as a testing
partner. The Pilot Program, which is designed to increase transparency,
interoperability and product identification within the medical cannabis industry,
uses TruTrace's StrainSecure™ technology as a central hub for identity
management, asset tracking, validation, and product authentication.
"Sigma
has been advancing the understanding of cannabis chemistry and has established a global scientific network of
pioneers to facilitate standardizing testing and quality assurance in this new and promising field of science,"
said Ashton Abrahams, Chief Operating Officer of Sigma Analytical.
"Working with TruTrace and Shoppers Drug Mart to track and trace the process
and products will have significant synergy with what Sigma is doing and will be
valuable to the fast-growing cannabis industry."
"We
are pleased to add Sigma Analytical as a partner in our StrainSecure
ecosystem," said TruTrace Technologies CEO Robert Galarza. "The Sigma
team has established a track record of innovation in the cannabis industry and
we look forward to collaborating with them as we continue to build out our
platform and processes."
As a
full-service testing and research GMP-compliant laboratory, Sigma Analytical
offers comprehensive testing and analytical services, as well as R&D, and
consulting in cannabis, hemp and derived products across North and South
America. Equipped with the most advanced analytical instruments and validated
SOPs, Sigma possesses a tremendous amount of acquired know-how and expertise in
the areas of cannabis and hemp sample preparation, processing, digestion,
method development, and analysis.
Under
the StrainSecure™ program, the TruTrace team collects plant testing data and
performs genomic verification in plant batches which are then registered in a
blockchain-enabled database for intellectual property protection and strain
validation. All information gathered from the plants, including their molecular
and chemical makeup, can be tracked via the program.
Village Farms
International, Inc. (TSX: VFF) (NASDAQ: VFF) announced that its 50%-owned joint venture for
large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has
begun shipping branded, packaged dried cannabis products to the British
Columbia Liquor Distribution Branch, which acts as the provincial wholesaler of
non-medical cannabis, supplying licensed private retailers and the
government-run online store and stand-alone BC Cannabis Stores. Pure Sunfarms
expects its first products to soon be available to retail customers in British
Columbia.
Pure
Sunfarms began shipping product to the Ontario provincial wholesaler, the
Ontario Cannabis Retail Corporation (the "OCRC", operating as the
Ontario Cannabis Store), in September.
Combined, Ontario and British Columbia comprise more than half of
Canada's population.
"It's
a testament to Pure Sunfarms' product quality, reputation and team, that in
less than four weeks following the long-awaited receipt of its license
amendment to sell directly to provincial wholesalers on September 6, it is now
shipping its proudly BC-grown product to its second provincial customer, adding
its home province of British Columbia to Canada's largest province, Ontario,
where its products are already available," said Michael DeGiglio, CEO,
Village Farms.
Pure
Sunfarms continues to advance discussions with other provincial distributors
for potential supply agreements to further expand its presence in the Canadian
cannabis market.
Aleafia Health Inc. (TSX: ALEF) (OTC: ALEAF) announced completing the construction of its Paris
Processing facility’s Phase II expansion and secured full site occupancy on
October 4, 2019, following the successful completion of County of Brant
inspections. The Paris Phase II expansion is a 30,000 sq. ft. facility entirely
dedicated to the extraction, production, packaging and distribution of
high-margin, value-added cannabis health and wellness products.
The
expansion builds upon the current, licensed and operational Paris facility,
which features cultivation rooms and handles all extraction, packaging and
order fulfillment for Aleafia Health’s medical, adult-use and international
sales.
Paris
will feature an initial 115,000 kg dried flower equivalent extraction capacity,
a 2,775 per cent increase over the Company’s current 4,000 kg DFE extraction
capacity. The Company expects that Paris can through-put all dried flower grown
by Aleafia Health, including at its newly expanded, 86-acre Port Perry Outdoor
Grow site.
To
complete the final stage of securing its required Licence Amendment, the
Company’s wholly-owned subsidiary, Emblem Cannabis Corp., expects to submit its
final evidence package to Health Canada this October, demonstrating the
facility’s operational readiness.
The
facility is purpose-built to meet European Union Good Manufacturing Practices
certification requirements. EU-GMP certified facilities demonstrate the highest
level of pharmaceutical-grade quality, and securing the certification will
allow Aleafia Health to begin exporting finished goods including cannabis oils
and capsules to the EU.
Through
the Aleafia Health Germany joint-venture with German pharmaceutical wholesaler
and logistics company Acnos Pharma GmbH, Aleafia will gain access to the
burgeoning German medical cannabis market, with access to 22,000 pharmacies and
110 distribution centres.
The
Paris expansion will rapidly accelerate Aleafia Health’s production capacity,
and ability to create a wide variety of differentiated products across multiple
categories. It has been built specifically to allow for further, significant
expansions of extraction capacity by utilizing additional machinery. For
instance, the existing capital expenditures budget accounts for additional
ethanol extraction machinery that would bring total capacity to 190,000 kg DFE
and would take approximately eight weeks to bring online.
“The
Paris expansion represents the crown jewel of Aleafia Health’s cannabis
ecosystem. This facility will allow us to rapidly expand the production of
high-margin derivative products, while adding new, differentiated formats that
are grown, processed, packaged and exported by Aleafia Health,” said CEO
Geoffrey Benic. “We look forward to bringing the next generation of cannabis
products to market, while greatly expanding our international footprint in
Germany, Australia and beyond.”
Emerald Health
Therapeutics’ (TSXV: EMH) (OTCQX: EMHTF) wholly-owned cannabis production
facility, Verdélite, in St. Eustache, Quebec, has received from Health Canada a license amendment for
the complete growing and processing area in its 88,000 square foot indoor
facility. The additional 50,000 square feet will allow Verdélite to expand
production from 4 to 21 highly-controlled-environment grow rooms and to a total
of 16 processing rooms. Planting in the newly licensed area is starting
immediately, with the plan focused on having the expanded facility fully
planted in eight weeks.
“Verdélite
is now fully built and licensed across all its growing and processing areas,
and I congratulate the team for this accomplishment,” said Thierry Schmidt,
President of Verdélite. “As we expand production of Emerald Health Therapeutics
products sold under the Emerald sales license, this step enables us to also
continue advancing our marketing strategy encompassing Verdélite brands and
direct sales to provincial/territorial wholesalers and authorized Canadian
private retailers.”
“This
new license amendment allows Verdélite to transition into its full commercial
phase and positions Verdélite as a key growth contributor to Emerald's
financial results in 2020,” said Riaz Bandali, Chief Executive Officer of
Emerald. “With this extended, controlled indoor growing space and Verdélite’s
unique cannabis strains, we aim to bring distinct and unique consumer-driven
products to the Quebec market.”
Verdélite
is a vertically integrated seed-to-sale indoor operation optimized for
year-round production of high-quality craft cannabis through its highly
controlled environment. Its established packaging and processing line are well
equipped to manage significant volume and a wide diversity of value-added
products.
Hemp, Inc. (OTC: HEMP), was recently featured in the renowned international news outlet,
United Press International (UPI), discussing the hemp industry and how Hemp,
Inc. is utilizing the crop beyond cannabidiol (CBD).
The
UPI article titled, “Hemp hardwoods, bioplastics expand crop
use beyond CBD”
discusses the current state of the hemp industry and expectations for the
future. The article promptly dives into the changing industry and the revised
route some farmers are taking to meet the growing demand to fully utilize the
newly legal crop's full potential.
The
article discussed the sprouting of businesses within various sectors of the
hemp industry such as hemp-based hardwood and bioplastics. The hemp bioplastics
industry is one Hemp, Inc. recently announced its entry into, marking it the
Company’s third venture into the natural product’s market.
The
article states, “The firm is milling a powdery bioplastic stock from hemp and
kenaf -- another natural-fiber plant. For now, the company imports from Europe
hemp hurd, a byproduct of hemp processing, and grinds it with kenaf.”
In
an interview with UPI, Hemp, Inc. CEO Bruce Perlowin discussed his excitement
upon entering this sector of the hemp industry, "I'm in heaven that we're
part of the supply chain to make bioplastic. I've been an environmentalist and
eco-commando since I was in high school."
Additionally,
the article highlights the Company’s operations in both North Carolina, where
the hemp bioplastics material is processed and the operations in Oregon, where
the company’s processing facility extracts CBD oil.
An
excerpt from the article states, “Before bioplastics companies can grow and
experiment with hemp-based products, a pathway has to be built from the plant
to the plastic, Perlowin said. There are too few hemp processing facilities to generate
the raw materials needed by plastic companies, he said.”
Perlowin
is quoted at the end of the UPI article explaining that Hemp, Inc. has one
machine at the North Carolina processing facility for hemp bioplastics, but
states there should be 200 others across the country to help fill the demand.
EnWave Corporation (TSX-V:ENW) today announced that NutraDried Food Company LLC, a
wholly-owned subsidiary of EnWave, will
install a third large-scale 120kW Radiant Energy Vacuum (“REV™”) machine to
expand production capacity for its rapidly growing Moon Cheese® snack
product line.
Moon
Cheese® is currently sold in over 25,000 points of distribution in
North America including premier retailers such as Starbucks, Costco, Whole
Foods, Publix, Target, and Wegmans. The
brand has also recently gained distribution at HEB, ShopRite, Sprouts, and
Raley’s. Moon Cheese is in the midst of a major brand re-launch reflecting
world-class new packaging, new varieties (Garlickin’ Parmesan and Cheddar Bacon
Me Crazy), and new sizes. The re-launch
has been enthusiastically received by retail partners and will be supported by
significant investments in sales and marketing.
NutraDried revenue has more than doubled in each of the past two years
and aggressive growth rates are expected to continue.
EnWave’s
Board of Directors has approved a capital investment budget of up to CA $8.0 MM
for the Company to construct a new 120kW nutraREV® machine and to
outfit the NutraDried manufacturing facility to allow for robust commercial
growth. The capital expansion will include upgrades to improve productivity and
will allow for the potential installation of two more nutraREV®
processing lines. This investment in the purpose-built commercial
infrastructure today will allow for up to a total of five nutraREV®
machines to be commissioned to address commercial growth. At the completion of
the initial expansion
NutraDried
will have three large-scale nutraREV® machines in commercial
production.
With
over $20 million of cash on hand, EnWave has ample capital available to support
and optimize the investment. The
increased manufacturing capacity will enable continued distribution and
velocity growth of the Moon Cheese® brand.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement to
buy products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available
on iTunes, Spotify, Google Play Music,
Stitcher, Spreaker, YouTube via
Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big
Investing Ideas Investorideas.com is a recognized news source
publishing third party news, research and original financial content. Learn
about investing in stocks and sector trends with our news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast and column, Cleantech and
Climate Change , Exploring Mining
the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
